Review article: anti-adhesion therapies for inflammatory bowel disease

643 Integrated Safety Analysis of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease

(2015) Jean-Frederic Colombel et al.   GASTROENTEROLOGY

159 Differentiation Between Etrolizumab (Rhumab Beta7) and Placebo in the Eucalyptus Phase II Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate Efficacy and Safety in Patients With Refractory Moderate-to-Severely Active Ulcerative Colitis

(2015) Severine Vermeire et al.   GASTROENTEROLOGY

Pharmacology of AMG 181, a human anti-α4β7antibody that specifically alters trafficking of gut-homing T cells

(2013) WJ Pan et al.   BRITISH JOURNAL OF PHARMACOLOGY

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Effect of Tumor Necrosis Factor-α Blockade on Mucosal Addressin Cell-adhesion Molecule-1 in Crohnʼs Disease

(2013) Paolo Biancheri et al.   INFLAMMATORY BOWEL DISEASES

Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease

(2013) Asit Parikh et al.   INFLAMMATORY BOWEL DISEASES

11 Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial

(2013) B. Sands et al.   Journal of Crohns & Colitis

Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice

(2013) Toshihiko Sugiura et al.   Journal of Crohns & Colitis

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease

(2013) Satish Keshav et al.   PLoS One

One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

(2012) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Decreasing Colectomy Rates for Ulcerative Colitis: A Population-Based Time Trend Study

(2012) Gilaad G Kaplan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry

(2012) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

(2012) Paul J Rutgeerts et al.   GUT

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

(2012) Axel Dignass et al.   Journal of Crohns & Colitis

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: remission rates achievable by current therapies for inflammatory bowel disease

(2011) L. Peyrin-Biroulet et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes

(2011) EG Stefanich et al.   BRITISH JOURNAL OF PHARMACOLOGY

The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

(2011) S. Vermeire et al.   GUT

Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease

(2011) L. Peyrin-Biroulet et al.   GUT

Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study

(2011) Asit Parikh et al.   INFLAMMATORY BOWEL DISEASES

Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease

(2011) Chadwick Williams et al.   Therapeutic Advances in Gastroenterology

Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis

(2011) Saskia Thomas et al.   INFLAMMOPHARMACOLOGY

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

(2010) A. Dignass et al.   Journal of Crohns & Colitis

Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease

(2010) M. J. Walters et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Review: Anti-adhesion molecule therapy for inflammatory bowel disease

(2010) Subrata Ghosh et al.   Therapeutic Advances in Gastroenterology

Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine

(2009) M. WAHED et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease

(2009) Millie D. Long et al.   Clinical Gastroenterology and Hepatology

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

(2009) Gert Van Assche et al.   Journal of Crohns & Colitis

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

(2009) Laurent Beaugerie et al.   LANCET

Adverse Events Associated With the Use of Cyclosporine in Patients With Inflammatory Bowel Disease

(2008) Michael B. Sternthal et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab

(2008) Maria del Pilar Martin   ARCHIVES OF NEUROLOGY

Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin

(2008) Brian G. Feagan et al.   Clinical Gastroenterology and Hepatology

European evidence-based Consensus on the management of ulcerative colitis: Special situations

(2008) Livia Biancone et al.   Journal of Crohns & Colitis